← Back to Search

Alpha-2 Adrenergic Agonist

Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed

Phase 1
Waitlist Available
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this test will be repeated every 15 minutes for 90 minutes after the subject has awakened]

Summary

This trial is testing if a combination of Atipamezole and caffeine can help healthy people wake up faster from anesthesia. Atipamezole reverses sedation, and caffeine increases alertness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this test will be repeated every 15 minutes for 90 minutes after the subject has awakened]
This trial's timeline: 3 weeks for screening, Varies for treatment, and this test will be repeated every 15 minutes for 90 minutes after the subject has awakened] for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The time when the drug injections are complete to the awakening of the subject.
Secondary study objectives
Measure Cognitive Function
Measure Reaction Time

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Phase 1: Atipamezole & caffeine's in a 1:1 ratioActive Control1 Intervention
Is this arm, subjects will be randomized to IV administration of Atipamezole \& caffeine's in a 1:1 ratio
Group II: Phase 1: Precedex & Saline in a 1:1 ratioPlacebo Group1 Intervention
Is this arm, subjects will be randomized to receive IV administration of Precedex \& Saline in a 1:1 ratio

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,062 Previous Clinical Trials
840,134 Total Patients Enrolled
~0 spots leftby Apr 2026